208 related articles for article (PubMed ID: 17581919)
1. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
Chung Y; Qin H; Kang CY; Kim S; Kwak LW; Dong C
Blood; 2007 Sep; 110(6):2013-9. PubMed ID: 17581919
[TBL] [Abstract][Full Text] [Related]
2. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
[TBL] [Abstract][Full Text] [Related]
4. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory.
Jing W; Gershan JA; Johnson BD
Blood; 2009 Apr; 113(18):4449-57. PubMed ID: 19182203
[TBL] [Abstract][Full Text] [Related]
5. A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells.
Grille S; Brugnini A; Nese M; Corley E; Falkenberg FW; Lens D; Chabalgoity JA
Cancer Immunol Immunother; 2010 Apr; 59(4):519-27. PubMed ID: 19768458
[TBL] [Abstract][Full Text] [Related]
6. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
7. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
Briones J; Timmerman JM; Panicalli DL; Levy R
J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
[TBL] [Abstract][Full Text] [Related]
8. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
9. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.
Renukaradhya GJ; Khan MA; Vieira M; Du W; Gervay-Hague J; Brutkiewicz RR
Blood; 2008 Jun; 111(12):5637-45. PubMed ID: 18417738
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect.
Hu G; Liu Y; Li H; Zhao D; Yang L; Shen J; Hong X; Cao X; Wang Q
Cell Mol Immunol; 2010 Jul; 7(4):296-305. PubMed ID: 20418899
[TBL] [Abstract][Full Text] [Related]
11. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
12. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
13. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.
Liu K; Idoyaga J; Charalambous A; Fujii S; Bonito A; Mordoh J; Wainstok R; Bai XF; Liu Y; Steinman RM
J Exp Med; 2005 Dec; 202(11):1507-16. PubMed ID: 16330814
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
16. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.
Hong C; Lee H; Oh M; Kang CY; Hong S; Park SH
J Immunol; 2006 Nov; 177(10):6747-57. PubMed ID: 17082588
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
19. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
Wang XY; Kazim L; Repasky EA; Subjeck JR
Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
